The semaglutide patent in India is set to expire in March 2026 (specifically on March 20), paving the way for a major influx of affordable alternatives to blockbuster drugs like Ozempic, Wegovy, and Rybelsus (from Novo Nordisk). This active ingredient of the drug, a GLP-1 receptor agonist used for type 2 diabetes management and weight loss, will soon face intense competition from domestic manufacturers.
Industry experts believe that over 50 branded generic versions may enter the Indian market shortly after the expiry of Novo Nordisk’s patent in India. Leading Indian pharma companies such as Sun Pharmaceutical Industries, Zydus Lifesciences, Dr. Reddy’s Laboratories, Lupin, Torrent Pharmaceuticals, Alkem Laboratories, and others are expected to launch their generic versions soon. Examples of anticipated brand names include:
Noveltreat and Sematrinity (Sun Pharma)
Semaglyn, Mashema, and Alterme (Zydus)
Semaglide (Alkem)
Semastar (Torrent)
Diagluton (Dr. Reddy’s), among many more.
The launch of generic versions is expected to drive significant price reductions — potentially 40-60% lower than current branded options — making treatment more accessible for diabetes and obesity patients.
Current monthly costs for original branded versions can range from ₹8,800-₹16,400 depending on dosage. Generic versions are expected to drop the cost to around ₹3,000-₹5,000 or less per month in many cases.
The expiry of Novo’s patent may mark a transformative moment for India’s diabetes and obesity care landscape, boosting adoption of GLP-1 therapies amid rising chronic disease prevalence. Launches of the generic versions are expected to begin almost immediately post-expiry, intensifying competition and expanding market reach.
